We are pleased to share with you highlights of the first International Conference of Cellvizio®
Users in this special edition of Cellvizio News. The conference proved to be an exciting forum for peer- to-peer learning.
The weekend was filled with discussions and debates challenging conventional thinking and practice,
and incorporated today's experience from the world's authoritative GI physicians.
Importantly, this dialog will carry forward throughout the year on Cellvizio.net,
our recently launched interactive online knowledge data- base.
With new clinical results to be announced at the major con- ferences in the following months,
we anticipate growing interest in the wide range of Cellvizio applications.
Sacha Loiseau, PhD,
President, CEO and Founder
|
VisualSonics to Sell
Mauna Kea Technologies' Cellvizio® LAB
on a Worldwide Basis
Mauna Kea Technologies and VisualSonics announced that they have entered an exclusive
distribution agree- ment through which Visual- Sonics will market and sell
Cellvizio LAB high resolution in vivo imaging systems to pre-clinical researchers.
Click here to read more
|
|
 |
|
Several new papers on Cellvizio have been published.
Thiberville et al. (2009).
Human in-vivo fluorescence microimaging of the alveolar ducts and sacs during bronchoscopy.
European Respiratory Journal.
Meining et al. (2009).
Pancreaticoscopy with miniprobe-based confocal laser-scanning microscopy of an intraductal papillary mucinous neoplasm (with video).
Gastrointest Endoscopy.
Monkemuller et al. (2009).
Endoscopic examination of the small bowel: from standard white light to confocal endomicroscopy.
Clinical Gastroenterology and Hepatology.
See the entire
bibliography here
|
|
|
|
|
|
|
First ICCU Meeting to advance probe-based Confocal Laser Endomicroscopy (pCLE) practice
More than forty top GI endoscopists from around the world gathered in Miami in February for the first
International Conference of Cellvizio Users (ICCU).
Co-chaired by Paul Fockens, M.D. from the Academic Medical Center in Amsterdam,
and Michael Wallace, M.D., from Mayo Clinic in Jacksonville, the conference achieved its goals,
among which, to advance agreement on the interpretation of Cellvizio images.
The conference provided a forum for discussions about current and future applications of
probe-based Confocal Laser Endomicroscopy (pCLE) including Barrett's Esophagus, bile and pancreatic duct diseases,
endoscopic mucosal resection (EMR), colonic polyps and inflammatory bowel diseases.
A key takeaway from the Conference was the potential of Cellvizio's impact on biopsy targeting and its potential to
eventually improve upon some historic histologic practices to diagnose certain gastrointestinal diseases.
|
|
 |
|
|
Cellvizio.net Launched
New Interactive Database Designed to Sustain pCLE Dialogue and Education
During the ICCU, the company launched a new online user community -
Cellvizio.net -
to continue the dialogue on pCLE that started at the conference.
The interactive site enables physicians to learn more about Cellvizio image interpretation, discuss and debate Cellvizio
images, and share findings within the Cellvizio user community.
Cellvizio.net currently offers its users the following:
|
Atlas:
A growing library of Cellvizio video clips, organized by organ and described with the
corresponding clinical, endosco- pic and endomicroscopic infor- mation provided by Cellvizio users.
|
|
Case Studies:
Specific and well-documented Cellvizio cases, published by the Cellvizio.net team, based on submissions or requests from Cellvizio users.
Case studies include endoscopic videos or images,
histopathology-confirmed diagnoses and subsequent patient management.
|
|
Grand Rounds:
A forum where users can submit cases, for open discussions and comments.
The most interesting cases can then be enhanced with endoscopy videos, histology, and eventually stored as case studies.
We will modify and expand these offerings pending feedback from our current users.
|
|
|
|
|
Barrett's findings
Participants determined that Cellvizio could respond to the need for a way to more reliably exclude neoplasia from the Barrett's segment and to reduce the number of random biopsies thereby lowering the associated costs.
Participants also postulated that Cellvizio's ability to capture images of living cells in real time may lead to a greater understanding of biomarkers that predict disease progression in Barrett's esophagus.
Several centers in the U.S. and Europe are currently comparing the accuracy of pCLE to white light and narrow band imaging in a prospective, multicenter trial.
ERCP findings
ICCU attendees concluded that Cellvizio has the potential to overcome the shortfalls of current bile and pancreatic duct cancer detection modalities, which are particularly prone to low diagnostic accuracy. In contrast, they pointed out that large irregular microvessels appear in Cellvizio images of malignant strictures, while benign tissue appears to have a very regular, reticular pattern when seen through pCLE.
A large, multi-center trial is underway in the U.S. and Europe to further define the diagnostic criteria for the images.
Cellvizio's Potential Role in Other GI Conditions
Cellvizio may also play a role in a series of other novel applications for its ability to
potentially characterize suspicious tissue and eliminate unnecessary biopsies or to monitor and assess treatment outcomes.
Other potential novel applications include detection of early rejection in small bowel transplantation,
detection of microscopic colitis, better comprehension of fistulas & leaks, and detection of celiac disease.
Cellvizio may also play an important role in endoscopic mucosal resection (EMR).
pCLE technology can be utilized before EMR to assess the margins and pathology of the segment and then to help
the endoscopist determine whether all the malignant/pre-malignant tissue was removed and to determine baseline pathology
of the region. Cellvizio can also be used during follow up, to assess residual neoplasia.
|
|
|
|
